The π-HuB Secretariat is pleased to share an important recent advance in clinical proteomics led by Professor Matthias Mann, a member of the π-HuB International Council, together with colleagues from the Max Planck Institute of Biochemistry, the Technical University of Munich, and international collaborating institutions.

Published in Cell in 2026, the study, entitled “Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis,” represents a major effort to apply high-throughput proteomics to clinically complex neurological diseases. By analyzing cerebrospinal fluid (CSF) samples from more than 5,000 individuals across multiple disease categories, the investigators demonstrate how large-scale, unbiased proteomic profiling can contribute to improved diagnosis, disease staging and therapeutic target discovery in multiple sclerosis (MS).

A clinically relevant cross-disease proteomics framework

One of the most notable strengths of the study is its broad cross-disease design. Rather than comparing MS only with healthy controls, the investigators analyzed samples from individuals with MS, other autoimmune disorders, neurodegenerative diseases, infections, brain tumors, stroke and neurological control conditions, together with an independent validation cohort.

This design addresses an important real-world clinical challenge: patients suspected of having MS often present with symptoms and inflammatory features that overlap with other neurological diseases. By studying MS within a broad differential diagnosis landscape, the work provides a more rigorous and clinically meaningful basis for identifying disease-relevant proteomic signals.

The large cohort also enabled the researchers to examine important sources of biological and clinical variation. In particular, impairment of the blood-CSF barrier emerged as a major determinant of CSF proteome variation, alongside factors such as age, sex and leukocyte count. Careful modeling of these variables allowed the study to distinguish disease-associated changes from broader physiological or pathological influences. This represents a valuable methodological lesson for future large-cohort proteomics studies.

From discovery proteomics to clinically compatible validation

Using scalable data-independent acquisition mass spectrometry workflows, the investigators generated high-quality proteomic profiles across thousands of CSF samples. From these data, they identified a 22-protein biomarker panel capable of distinguishing MS from related inflammatory neurological diseases.

Importantly, the panel demonstrated particular value in oligoclonal band-negative patients, a diagnostically challenging subgroup in which existing clinical markers may provide limited support. The study therefore illustrates the potential of proteomics not merely to reproduce established clinical information, but to improve diagnostic resolution in difficult clinical situations.

The researchers further validated the protein panel in an independent cohort using a targeted mass spectrometry assay with isotope-labeled standards. This progression from large-scale discovery to targeted analytical validation is especially significant. It provides a practical translational pathway through which proteomics-derived findings may be developed into robust and clinically applicable assays.

Beyond diagnosis, the study also explored the use of proteomic information to characterize disease progression. Through proteome-based staging, the investigators were able to position individuals along the relapsing-to-progressive MS spectrum, with associations to clinical disability and the risk of progression. In addition, the analysis highlighted several proteins of potential therapeutic relevance, opening opportunities for future mechanistic investigation and possible therapeutic development or repurposing.

Relevance for the scientific mission of π-HuB

This study is highly relevant to the scientific vision and future implementation of π-HuB. It demonstrates the value of combining large-scale cohort design, standardized high-throughput proteomics, rigorous analytical modeling, targeted validation and clinically meaningful interpretation within a single integrated research framework.

Several elements are particularly instructive for future collaborative work: the importance of studying diseases within realistic clinical comparison groups; the need to systematically account for biological and technical confounding factors; the value of scalable and reproducible workflows; and the necessity of linking discovery studies with validation and translational application.

As π-HuB moves into implementation, such advances reinforce the potential of proteome navigation to contribute to disease understanding, patient stratification, early diagnosis and precision intervention. They also highlight the importance of international collaboration in assembling high-quality cohorts, harmonizing analytical standards, sharing data and expertise, and accelerating the translation of proteomics discoveries into medical benefit.